Your browser is no longer supported. Please, upgrade your browser.
Settings
ALDX Aldeyra Therapeutics, Inc. daily Stock Chart
ALDX [NASD]
Aldeyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own1.90% Shs Outstand14.96M Perf Week0.00%
Market Cap66.57M Forward P/E- EPS next Y-1.84 Insider Trans340.37% Shs Float14.93M Perf Month-6.32%
Income-18.80M PEG- EPS next Q-0.39 Inst Own52.00% Short Float1.03% Perf Quarter-11.88%
Sales- P/S- EPS this Y-17.60% Inst Trans28.49% Short Ratio1.42 Perf Half Y-6.61%
Book/sh2.03 P/B2.19 EPS next Y-16.50% ROA- Target Price19.20 Perf Year-13.42%
Cash/sh2.09 P/C2.13 EPS next 5Y- ROE- 52W Range3.80 - 8.19 Perf YTD-16.82%
Dividend- P/FCF- EPS past 5Y-31.70% ROI- 52W High-45.66% Beta-
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low17.11% ATR0.31
Employees6 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)45.71 Volatility5.17% 6.29%
OptionableNo Debt/Eq0.05 EPS Q/Q27.90% Profit Margin- Rel Volume0.33 Prev Close4.45
ShortableYes LT Debt/Eq0.04 EarningsMay 15 BMO Payout- Avg Volume108.18K Price4.45
Recom1.60 SMA20-7.15% SMA50-1.72% SMA200-16.91% Volume35,392 Change0.00%
Sep-26-16Initiated H.C. Wainwright Buy $18
Jul-01-16Initiated Stifel Buy $16
Jul-01-15Initiated Canaccord Genuity Buy $16
Mar-25-15Initiated Chardan Capital Markets Buy $16
Mar-20-15Reiterated H.C. Wainwright Buy $13 → $14
Nov-18-14Initiated H.C. Wainwright Buy $13
Jun-19-14Initiated Aegis Capital Buy $35
Jun-19-17 08:00AM  Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting PR Newswire
Jun-14-17 10:05AM  US STOCKS-Wall St flat as banks fall after weak data; Fed eyed Reuters -8.82%
10:05AM  Aldeyra Stumbles Over Mid-Stage Clinical Results 24/7 Wall St.
09:36AM  Aldeyra Therapeutics stock drops 16% after mid-stage trial miss MarketWatch
06:50AM  Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing PR Newswire
Jun-13-17 04:30PM  Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial PR Newswire
Jun-06-17 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial PR Newswire
May-26-17 10:26AM  Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet Zacks
May-25-17 07:23AM  Horizon (HZNP) Sells European Rights for Procysbi & Quinsair Zacks
May-23-17 04:06PM  Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint Zacks +5.75%
May-17-17 08:00AM  Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting Marketwired
May-15-17 07:30AM  Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results Marketwired +5.06%
07:00AM  Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call Accesswire
May-08-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results Marketwired
Apr-27-17 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial Marketwired
Apr-20-17 08:00AM  Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome Marketwired -16.35%
Apr-18-17 08:00AM  Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial Marketwired
Mar-30-17 08:08AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
08:00AM  Aldeyra Therapeutics Reports Full Year 2016 Financial Results Marketwired
07:07AM  Q4 2016 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
Mar-22-17 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results Marketwired
Feb-28-17 08:00AM  Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference Marketwired
Feb-22-17 10:33AM  Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading Insider Monkey
10:33AM  Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading at Insider Monkey
08:00AM  Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome Marketwired
Feb-17-17 04:09PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Marketwired
Feb-14-17 06:11PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -5.06%
09:39AM  Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock Marketwired
Feb-13-17 04:31PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock Marketwired
Feb-07-17 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial Marketwired
Feb-06-17 08:00AM  Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day Marketwired
Jan-25-17 08:07AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs Marketwired
Dec-15-16 09:47AM  Is Carolina Bank Holding Inc. (NC) (CLBH) A Good Stock To Buy? at Insider Monkey
Dec-05-16 11:42AM  Aldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
Nov-22-16 08:00AM  Aldeyra Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference Marketwired -6.35%
Nov-18-16 01:04PM  ALDEYRA THERAPEUTICS, INC. Financials +6.09%
Nov-14-16 07:51AM  Aldeyra reports 3Q loss +8.30%
07:39AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:30AM  Aldeyra Therapeutics Announces Third Quarter 2016 Financial Results Marketwired
07:07AM  Q3 2016 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
Nov-09-16 08:00AM  Aldeyra Therapeutics to Present at the Stifel 2016 Healthcare Conference Marketwired
Nov-08-16 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results Marketwired
Nov-07-16 08:00AM  Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Marketwired +12.26%
Nov-03-16 10:32AM  Aldeyra Therapeutics (ALDX) is Oversold: Can It Recover?
Sep-26-16 08:36AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
08:30AM  Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day Marketwired
07:14AM  Coverage initiated on Aldeyra Therapeutics by H.C. Wainwright
Sep-21-16 01:22PM  Aldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 21, 2016
08:45AM  Aldeyra Therapeutics (ALDX) Worth a Look: Stock Gains 7%
Sep-14-16 07:41AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex +5.87%
07:30AM  Aldeyra Therapeutics Appoints Richard H. Douglas to Its Board of Directors Marketwired
Sep-09-16 08:00AM  Aldeyra Therapeutics Announces 2016 Research and Development Day Marketwired
Sep-02-16 07:01AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Aug-10-16 07:11AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q2 2016 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Aldeyra Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update Marketwired
Aug-09-16 07:09AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
07:00AM  Aldeyra Therapeutics Announces Positive Results from a Randomized, Double-Blind, Vehicle-Controlled Clinical Trial of Topical Dermatologic NS2 in Patients With Sjögren-Larsson Syndrome Marketwired
Aug-08-16 04:00PM  Aldeyra Therapeutics Schedules Conference Call to Present Results of a Randomized, Double-Blind, Vehicle-Controlled Clinical Trial in Sjogren-Larsson Syndrome Marketwired
Aug-04-16 10:01AM  Aldeyra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference Marketwired
Aug-03-16 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2016 Financial and Operating Updates Marketwired
Jul-28-16 04:05PM  Spring Bank Pharmaceuticals Appoints Dr. Todd C. Brady to its Board of Directors GlobeNewswire
Jun-10-16 05:04PM  Aldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016
04:07PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-07-16 08:00AM  Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Phase II Clinical Trial of Topical Dermatologic NS2 in Patients With Sjögren-Larsson Syndrome Marketwired +5.89%
Jun-01-16 04:01PM  Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter Overallotment Option Marketwired
May-27-16 06:15AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St +10.85%
May-26-16 08:50AM  Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock Marketwired
May-25-16 04:01PM  Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock Marketwired +5.88%
May-09-16 07:47AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or
07:30AM  Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis Marketwired
07:18AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
May-05-16 04:14PM  Aldeyra Therapeutics Schedules Webcast and Conference Call for First Quarter 2016 Financial and Operating Updates Marketwired
Apr-04-16 09:15AM  Why Aldeyra Therapeutics Could Have Exponential Upside at 24/7 Wall St. +6.13%
Mar-31-16 07:33AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-30-16 09:44AM  Edited Transcript of ALDX earnings conference call or presentation 30-Mar-16 12:30pm GMT
07:50AM  Aldeyra Therapeutics Reports Full Year 2015 Financial Results at noodls
07:32AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:30AM  Aldeyra Therapeutics Reports Full Year 2015 Financial Results GlobeNewswire
07:07AM  Q4 2015 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
Mar-24-16 08:38AM  Aldeyra Therapeutics to Present at the 2016 SSADH Symposium at noodls
08:30AM  Aldeyra Therapeutics to Present at the 2016 SSADH Symposium GlobeNewswire
Mar-18-16 05:02PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Mar-16-16 08:30AM  Aldeyra Therapeutics Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Mar-15-16 08:50AM  Is a Surprise Coming for Aldeyra Therapeutics (ALDX) This Earnings Season?
Mar-14-16 11:00AM  What's in Store for Catalyst (CPRX) this Earnings Season? +14.92%
10:20AM  Adobe Systems (ADBE): A Surprise in Q1 Earnings Release?
Mar-09-16 08:02AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,
Mar-03-16 08:30AM  Aldeyra Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire
Feb-29-16 12:02PM  Aldeyra's eye drug effective in mid-stage trial; shares soar +31.29%
11:11AM  Aldeyra Therapeutics Surges 38%: Here's Why
07:33AM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
07:16AM  Aldeyra's eye drug found effective in mid-stage study
07:00AM  Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis GlobeNewswire
Feb-09-16 08:30AM  Aldeyra Therapeutics Appoints Mary Taylor, MPH as Senior Vice President, Regulatory Affairs GlobeNewswire -6.09%
Feb-02-16 04:08PM  ALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.83%
Jan-11-16 08:30AM  Aldeyra Therapeutics Appoints David J. Clark, M.D. as Chief Medical Officer GlobeNewswire
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjogren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOUGLAS RICHARDDirectorFeb 17Buy4.5040,000180,00040,000Feb 21 04:33 PM
Brady Todd CPresident and CEOFeb 17Buy4.5022,223100,00464,408Feb 21 04:32 PM
Bronstein BenDirectorFeb 17Buy4.504,44419,99816,944Feb 21 04:31 PM
Tulipano Stephen JChief Financial OfficerFeb 17Buy4.503,33314,9993,333Feb 21 04:30 PM
JOYCE MARTIN JOSEPHDirectorFeb 17Buy4.504,44419,99817,944Feb 21 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 14Buy4.50893,0254,018,6132,589,451Feb 15 08:45 AM